Evaluation of Cardiometabolic Risk in Patients with Non-Functioning Adrenal Adenomas Using the Systematic Coronary Risk Evaluation 2 (SCORE2) and the Systematic Coronary Risk Evaluation 2-Older Persons (SCORE2-OP) Algorithms

使用系统性冠状动脉风险评估 2 (SCORE2) 和系统性冠状动脉风险评估 2-老年人 (SCORE2-OP) 算法评估无功能性肾上腺腺瘤患者的心血管代谢风险

阅读:1

Abstract

BACKGROUND Non-functioning adrenal adenomas (NFA) are prevalent tumors often associated with metabolic disturbances compared to the general population. This study aimed to evaluate cardiovascular disease (CVD) risk in 106 patients with NFA using SCORE2 and SCORE2-OP algorithms. MATERIAL AND METHODS The study sample comprised of 106 patients with NFA. CVD risk was assessed using SCORE2 and SCORE2-OP charts. The study population was divided across different categories: low-to-moderate risk, high-risk, very high-risk of CVD. Anthropometric measurements, metabolic indices, lipid profiles, and carbohydrate metabolism parameters were analyzed across different CVD risk groups. RESULTS Very high-risk patients had a higher waist-to-hip ratio (WHR) value (0.95; 0.89-0.98) compared to low-to-moderate risk patients (0.89; 0.84-0.91; P=0.0049). Also, high-risk patients had a higher WHR value (0.92; 0.87-0.97) compared to low-to-moderate risk patients (0.89; 0.84-0.91; P=0.032). Patients with low-to-moderate CVD risk had significantly lower fasting glucose levels compared to patients with high CVD risk (5.35; 5.08-5.61 vs 5.78; 5.39-6.03; P=0.0093) as well as compared to patients with very high risk (5.35; 5.08-5.61 vs 5.83; 5.22-6.28; P=0.0230). There was no significant difference in lipid parameters and atherogenic indices between the groups based on CVD risk according to SCORE2 and SCORE2-OP. CONCLUSIONS Elevated fasting glucose levels are significantly associated with higher CVD risk in NFA patients, particularly in high and very high-risk group. Systolic blood pressure and WHR were identified as cost-effective measures for predicting of CVD among NFA patients. Metabolic indices did not show any significant differences across CVD risk groups.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。